Opinion|Videos|July 15, 2024
Financial and Clinical Benefits of RSV Immunization
Following the recent approval of RSV vaccines, the panel discusses the financial and clinical benefits, highlighting the fiscal impact seen in hospitals and ICUs.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- With RSV vaccines newly approved, what are the financial and clinical goals associated with immunizing against RSV?
- Have payers activated early coverage for the adult RSV vaccines since they entered to reduce costs?
- How have RSV vaccines altered the fiscal impact associated with managing RSV infections in hospitals or ICUs?
- How have RSV vaccines altered the fiscal impact associated with managing RSV infections in hospitals or ICUs?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
TrumpRx Launch Brings Savings—and Uncertainty
2
How Do GLP-1 Agonists Fit Into Stroke Care?
3
5 Things to Know About the Oral GLP-1 Era
4
Stroke Subtype Does Not Affect Efficacy of Asundexian for Second Stroke Prevention
5
